1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
Delayed Nyse  -  04:03 2022-08-11 pm EDT
142.08 USD   +0.81%
08/11AbbVie's Eye Disease Drug Recommended For Extended Use In British Healthcare System
MT
08/11The Seventh Circuit Asks, "What's Wrong With Having Lots Of Patents?"
AQ
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie Says EMA's Committee Supports Approval of Upadacitinib for Treatment of Chronic Inflammatory Disease of the Spine

06/27/2022 | 04:30am EDT


© MT Newswires 2022
All news about ABBVIE INC.
08/11AbbVie's Eye Disease Drug Recommended For Extended Use In British Healthcare System
MT
08/11The Seventh Circuit Asks, "What's Wrong With Having Lots Of Patents?"
AQ
08/11Senate Finance Committee looks at Amgen taxes, widening drugmaker probe
RE
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/09Few U.S. patients with hepatitis C get timely treatment, CDC says
RE
08/09Arecor Granted EU Patent Protection for High-Concentration Version of AbbVie's Adalimum..
MT
08/05FOCUS : 5 Stocks for Yield Lovers
MS
08/04ABBVIE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
08/04AbbVie's Humira Patent Settlement Not A Violation Of Sherman Antitrust Act, Seventh Cir..
AQ
08/04GLOBAL MARKETS LIVE : Bayer, Merck, eBay, MetLife, Eli Lilly...
MS
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2022 59 077 M - -
Net income 2022 12 430 M - -
Net Debt 2022 54 894 M - -
P/E ratio 2022 16,3x
Yield 2022 4,03%
Capitalization 251 B 251 B -
EV / Sales 2022 5,18x
EV / Sales 2023 5,36x
Nbr of Employees 50 000
Free-Float 97,4%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 142,08 $
Average target price 159,57 $
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Robert A. Michael Vice Chairman & President
Scott T. Reents Chief Financial Officer & Senior Vice President
Thomas J. Hudson VP, Head-Oncology Discovery & Early Development
Roxanne Schuh Austin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.4.93%251 211
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-16.39%272 759
PFIZER, INC.-18.22%271 020
NOVO NORDISK A/S6.37%248 905